Equities analysts expect that Myriad Genetics, Inc. (NASDAQ:MYGN) will post $0.26 earnings per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Myriad Genetics’ earnings, with the lowest EPS estimate coming in at $0.23 and the highest estimate coming in at $0.27. Myriad Genetics posted earnings per share of $0.36 in the same quarter last year, which suggests a negative year over year growth rate of 27.8%. The company is expected to issue its next quarterly earnings results on Tuesday, August 8th.

According to Zacks, analysts expect that Myriad Genetics will report full-year earnings of $1.02 per share for the current fiscal year, with EPS estimates ranging from $0.99 to $1.05. For the next fiscal year, analysts anticipate that the business will post earnings of $1.07 per share, with EPS estimates ranging from $0.85 to $1.30. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Myriad Genetics.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, May 2nd. The company reported $0.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.03. Myriad Genetics had a return on equity of 10.53% and a net margin of 4.26%. The business had revenue of $196.90 million for the quarter, compared to the consensus estimate of $188.89 million.

A number of research firms have recently commented on MYGN. Piper Jaffray Companies restated a “hold” rating and set a $22.00 target price on shares of Myriad Genetics in a research report on Friday, July 14th. BidaskClub lowered shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $21.00 price target (up from $18.00) on shares of Myriad Genetics in a research note on Wednesday, May 3rd. Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research note on Monday, July 17th. Finally, Cowen and Company reaffirmed a “hold” rating and issued a $25.00 price target on shares of Myriad Genetics in a research note on Friday, July 14th. Five equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $22.00.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Parametrica Management Ltd acquired a new position in Myriad Genetics during the first quarter worth $236,000. Capstone Asset Management Co. acquired a new position in Myriad Genetics during the first quarter worth $336,000. Bank of Montreal Can raised its position in Myriad Genetics by 5.2% in the first quarter. Bank of Montreal Can now owns 112,150 shares of the company’s stock worth $2,154,000 after buying an additional 5,529 shares during the period. Creative Planning raised its position in Myriad Genetics by 11.8% in the first quarter. Creative Planning now owns 6,371 shares of the company’s stock worth $122,000 after buying an additional 671 shares during the period. Finally, Foundry Partners LLC raised its position in Myriad Genetics by 3.6% in the first quarter. Foundry Partners LLC now owns 22,500 shares of the company’s stock worth $432,000 after buying an additional 775 shares during the period.

Shares of Myriad Genetics (NASDAQ:MYGN) remained flat at $24.16 during trading on Monday. 819,313 shares of the stock traded hands. Myriad Genetics has a 12-month low of $15.15 and a 12-month high of $32.54. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of 51.62 and a beta of 0.32. The company has a 50-day moving average price of $24.27 and a 200 day moving average price of $20.02.

COPYRIGHT VIOLATION NOTICE: “Myriad Genetics, Inc. (NASDAQ:MYGN) Expected to Post Earnings of $0.26 Per Share” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/24/myriad-genetics-inc-nasdaqmygn-expected-to-post-earnings-of-0-26-per-share.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Get a free copy of the Zacks research report on Myriad Genetics (MYGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.